Mindfulness and Psilocybin: Why They Might Work Better Together

Depression doesn’t just lower your mood. It can change how you think and how you regulate emotion. Your body’s stress response shifts too, along with how connected you feel to other people. Even the way different networks in your brain talk to each other can change. That’s part of why one single treatment rarely fixes it.

A 2020 review by Kristin Heuschkel and Kim Kuypers of Maastricht University, published in Frontiers in Psychiatry, looked at two treatments that keep showing up in the same conversation: mindfulness meditation and psilocybin. Their central question was simple. Could mindfulness and psilocybin influence some of the same processes involved in depression, through different, potentially complementary mechanisms?

Here’s the short answer. Research suggests mindfulness and psilocybin may influence several of the same psychological and biological processes associated with depression, but through different mechanisms. Mindfulness, for instance, appears to build emotional and cognitive regulation gradually, while psilocybin may temporarily disrupt rigid patterns of thinking and brain-network activity. Because of this contrast, researchers have proposed that the two effects could complement one another, although no one has established the combination as a treatment for depression.

That distinction matters, and we’ll come back to it throughout this article.

Why Depression Needs More Than One Tool

The review’s authors cite an estimate that approximately 4.4% of the global population had depression at the time they wrote the paper in 2020. Worth being precise here: that’s the historical figure the researchers referenced, not necessarily today’s global rate, which shifts as new data comes in.

The Psychological and Biological Picture

According to the review, depression involves negative thinking patterns, poor emotion regulation, and excessive rumination. Together, these create a kind of cognitive rigidity. In addition, depression affects social functioning: people experiencing it often show differences in empathy and communication, and they tend to seek out feedback that reinforces a negative self-image.

Depression’s biology tells a similar story. Researchers link it to reduced neuroplasticity, which is the brain’s ability to adapt and form new connections. They also link it to imbalances between core brain networks involved in rumination and attention, plus a dysregulated stress response system marked by irregular cortisol patterns and elevated inflammation. Rather than acting independently, the authors describe these factors as feeding into each other in a loop. As a result, that loop helps explain why depression can resist treatment aimed at just one mechanism.

Conventional treatment reflects that limitation. For example, antidepressants target neurotransmitter levels, but they come with side effects and high relapse rates after people stop taking them. Similarly, psychotherapy helps many people, yet dropout and relapse remain considerable. Even when combined, generally more effective than either alone, a substantial number of patients still don’t reach full recovery.

How the Review Was Conducted

To identify the six factors above, the researchers searched PubMed and Google Scholar and found 1,129 records. After screening titles and abstracts for relevance, they narrowed that down sharply, then added more studies found through reference lists. In the end, 95 articles made up the final review (the abstract cites 93, likely a small discrepancy in how the paper tallied its count between sections). Worth flagging: 1,129 studies were surfaced by the search, but the team didn’t individually analyze all of them.

Mindfulness vs. Psilocybin: Same Destination, Different Roads

Across the six factors examined, the review found that mindfulness and psilocybin produce similar effects on mood, social skills, and neuroplasticity. However, they produce different effects on executive functioning, brain network activity, and stress and immune markers.

Mood and Emotional Regulation

Both practices reliably improve mood, but they take different routes. Specifically, mindfulness builds mental strategies over time, reducing the tendency to spiral into negative thinking while increasing acceptance of difficult emotions. Psilocybin’s mood effects, on the other hand, tend to come from something more acute: sessions can produce a “peak” experience, a sense of connectedness or insight, followed by a longer window of improved mood sometimes called an “afterglow.” In both cases, the effects seem to scale with “dose” in their own way, since more meditation practice and higher psilocybin doses both led to stronger effects.

Executive Function and Cognitive Flexibility

Here the two diverge. Mindfulness training strengthens working memory, attention, and inhibitory control fairly consistently. Psilocybin, by contrast, can acutely impair some of these same functions during the experience itself. Researchers believe this temporary loss of cognitive control may actually be part of the therapeutic mechanism, allowing suppressed emotions to surface. Because of this, the review doesn’t present combining the two here as a clear win. Mindfulness training might buffer that loss of control during a psilocybin session, or conversely, it might blunt some of psilocybin’s more cathartic effects. Either way, the evidence isn’t settled.

Social Connection and Empathy

Mindfulness improves how people behave in relationships, supporting better communication and less emotional reactivity to conflict. Psilocybin, meanwhile, works more on the internal side, boosting empathy and a sense of connectedness. Part of this happens through a phenomenon researchers call ego dissolution, a temporary loosening of the sense of self as separate from one’s surroundings. Together, these effects could complement each other: psilocybin shifts how people relate internally, while mindfulness reinforces that shift through outward behavior.

Neuroplasticity and the Brain’s Ability to Change

Psilocybin appears to trigger a rapid, short-lived surge in neuroplasticity through its action on serotonin 2A receptors. As a result, this may open a brief window where the brain becomes unusually receptive to change. Mindfulness, in contrast, builds neuroplasticity more gradually, through sustained practice. Given this difference, the review’s suggestion is intuitive: psilocybin might kick things off, and mindfulness might help sustain it.

The Default Mode Network and Rumination

Depression involves overactivity in the brain’s default mode network, the system active during rumination. Mindfulness and psilocybin both appear to loosen this network’s dominance, but through different paths: mindfulness through steady, top-down regulatory training, and psilocybin through a more acute, global disintegration of network activity.

One study cited in the review stands out. In it, researchers gave a single dose of psilocybin to healthy, experienced meditators, not patients with depression, during a five-day mindfulness retreat. Notably, the psilocybin-related brain changes, especially around ego dissolution and shifts in connectivity, predicted positive psychosocial functioning four months later. While it’s a genuinely interesting data point about how the two might interact in practice, it doesn’t prove the combination treats depression, since no comparable study exists yet in a depressed clinical population.

Cortisol and the Stress Response

Mindfulness research on cortisol has produced mixed results. Some studies show no change in healthy volunteers, while others show reductions in cancer patients under comparable programs. Meanwhile, at least one study found an increase in the cortisol awakening response in a specific patient group. Given these inconsistencies, the authors suggest mindfulness may not simply lower cortisol across the board, but rather help optimize how the stress response system functions overall.

Psilocybin shows a different pattern. Specifically, it causes an acute increase in cortisol during the psychedelic experience itself, even though some research reports reductions in subjective stress in the weeks and months afterward. That’s a useful distinction to sit with, because it reinforces this article’s broader point: mindfulness and psilocybin often affect the same underlying systems, but rarely through the same mechanism or timeline.

Inflammation

Psilocybin may influence inflammatory pathways through 5-HT2A receptor activity, since these receptors sit throughout the immune system. In line with this, related psychedelics, including LSD and DMT, showed anti-inflammatory effects in lab studies. However, the review is clear on one point: direct evidence for an anti-inflammatory effect of psilocybin itself was still lacking at the time of writing. In other words, this reasoning extrapolates from chemically related compounds acting on the same receptor, rather than reflecting a finding about psilocybin specifically.

Why Combining Mindfulness and Psilocybin Might Matter

The interesting finding isn’t simply that mindfulness and psilocybin produce similar effects. Rather, it’s that they may influence some of the same psychological and biological systems through very different mechanisms. Mindfulness generally works gradually, through repeated practice and top-down regulation, whereas psilocybin produces more acute changes in perception, cognition, emotional processing, and brain-network activity.

That contrast is precisely what makes the combination scientifically interesting. In theory, a gradual, practice-based approach and an acute, experience-based approach could reinforce each other rather than duplicate the same effect twice.

What the Research Does Not Yet Prove

The review’s authors are direct here: no study has tested mindfulness-based therapy combined with psilocybin in depressed patients. In other words, they’ve built a well-reasoned theoretical case for why that combination deserves testing, not a result showing that it works.

The underlying studies carry real limitations too. For instance, mindfulness research uses inconsistent methods and outcome measures across populations, which makes comparisons difficult. Meanwhile, many psilocybin studies involved small samples, open-label designs, or no control group, all of which limit how confidently anyone can generalize the findings. And because clinical settings always pair psilocybin with psychological support, it’s genuinely hard to separate the drug’s effects from the effects of the surrounding care.

For people interested in both mindfulness and psychedelics, the review offers a useful scientific framework for understanding how the two might interact. That said, whether the same complementary effects occur with microdosing remains a separate research question. The studies referenced here involve full, session-based doses taken in a supported setting, not the sub-perceptual amounts used in microdosing protocols, so the mechanisms described here shouldn’t be assumed to transfer directly.

What This Means for Mindfulness and Psychedelic Research

This review offers a valuable theoretical foundation, not a finished conclusion. Instead, it maps out where mindfulness and psilocybin overlap, where they diverge, and where a well-designed clinical trial could test whether the combination helps. Accordingly, the authors specifically call for randomized, placebo-controlled research comparing psilocybin-assisted mindfulness-based therapy to each treatment alone, and to conventional antidepressants.

Concepts like set and setting, psychedelic integration, and the brain’s default mode network show up throughout this line of research, and they’re worth understanding on their own if this topic interests you.

The Bottom Line

The review provides a theoretical framework, not proof that combining mindfulness and psilocybin treats depression. Nor does it establish that the same mechanisms apply to microdosing specifically.

What it does offer, though, is a well-reasoned case for why two very different approaches, one gradual and practice-based, one acute and experience-based, might influence the same underlying systems in complementary ways. That’s a meaningful contribution on its own, even without a clinical trial behind it yet.

Ultimately, controlled clinical research is the next necessary step, and the authors say so themselves. If you’re navigating depression, please talk to a healthcare provider, since research like this is one piece of a much larger picture, not a treatment protocol.

Source: Heuschkel, K., & Kuypers, K.P.C. (2020). Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review. Frontiers in Psychiatry, 11, Article 224. DOI: https://doi.org/10.3389/fpsyt.2020.00224

Written by Joseph Santiago, founder of Microdose Bros. Connect with me on LinkedIn.

If you found this useful, follow Microdose Bros for more research breakdowns and updates: